Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Introduction

The addition of bevacizumab to the first-line chemotherapy of advanced non-small cell lung cancer (NSCLC) of non-squamous histology has been shown to improve survival. A multicenter, single-arm, phase IV study was conducted in order to evaluate the efficacy and toxicity of frontline bevacizumab-based chemotherapy regimens in real life.

Methods

Patients with previously untreated recurrent or metastatic non-squamous, NSCLC, with no contraindications for bevacizumab, were enrolled. Bevacizumab (15 mg/kg every 3 weeks) was administered in combination with both platinum- and non-platinum-based chemotherapy doublets or with single-agent chemotherapy plus bevacizumab. Treatment with bevacizumab was continued until disease progression. The primary end point of the study was the safety profile of bevacizumab regimens, whereas the secondary end points included overall survival, progression-free survival, and overall response rate.

Results

From February 2010 to April 2014, a total of 314 patients were enrolled in the study; the median age was 63, 74.8 % were men, 95.9 % had a performance status of 0–1, 90.4 % had metastatic disease, and 94.3 % had adenocarcinoma. Grade ≥3 neutropenia occurred in 11.5 % of the patients, 1.3 % experienced febrile neutropenia, 2.6 % grade ≥3 thrombocytopenia, 2.8 % thromboembolism, and 1.6 % severe bleeding. Treatment discontinuation occurred in 7.0 % of patients because of adverse events. There were three toxic deaths. Median progression-free survival was 7.7 months, and median overall survival was 17.6 months.

Conclusion

The combination of bevacizumab with chemotherapy in the first-line setting of NSCLC is safe and active when used in appropriately selected patients.

Clinicaltrials.gov identifier

NCT01934465.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292(4):470–484. doi:10.1001/jama.292.4.470

    Article  CAS  PubMed  Google Scholar 

  2. Rajeswaran A, Trojan A, Burnand B, Giannelli M (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59(1):1–11. doi:10.1016/j.lungcan.2007.07.012

    Article  PubMed  Google Scholar 

  3. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13(16):1845–1857

    Article  CAS  PubMed  Google Scholar 

  4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550. doi:10.1056/NEJMoa061884

    Article  CAS  PubMed  Google Scholar 

  5. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21(9):1804–1809. doi:10.1093/annonc/mdq020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551. doi:10.1200/JCO.2007.15.0375

    Article  CAS  PubMed  Google Scholar 

  7. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP (2013) Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24(1):20–30. doi:10.1093/annonc/mds590

    Article  PubMed  Google Scholar 

  8. Lynch TJ Jr, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Hazard SJ, Kosty MP (2014) Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. J Thorac Oncol 9(9):1332–1339. doi:10.1097/JTO.0000000000000257

    Article  CAS  PubMed  Google Scholar 

  9. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11(8):733–740. doi:10.1016/S1470-2045(10)70151-0

    Article  CAS  PubMed  Google Scholar 

  10. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R (2013) PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 31(34):4349–4357. doi:10.1200/JCO.2012.47.9626

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikstrom A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31(24):3004–3011. doi:10.1200/JCO.2012.42.3749

    Article  CAS  PubMed  Google Scholar 

  12. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):141–151. doi:10.1016/S1470-2045(14)71173-8

    Article  CAS  PubMed  Google Scholar 

  13. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, da Chu T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105(9):595–605. doi:10.1093/jnci/djt072

    Article  CAS  PubMed  Google Scholar 

  14. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D (2008) Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 3(2):125–129. doi:10.1097/JTO.0b013e3181622c17

    Article  PubMed  Google Scholar 

  15. Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ (2015) PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 10(1):134–142. doi:10.1097/JTO.0000000000000366

    Article  CAS  PubMed  Google Scholar 

  16. Thadhani R, Tonelli M (2006) Cohort studies: marching forward. Clin J Am Soc Nephrol 1(5):1117-1123. doi:10.2215/CJN.00080106

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by investigational grants from the Cretan Association for Biomedical Research (CABR) and Hellenic Oncology Research Group (HORG).

Author information

Authors and Affiliations

  1. Hellenic Oncology Research Group (HORG), 55 Lomvardou Street, 11471, Athens, Greece

    A. Matikas, Ν. Kentepozidis, A. Ardavanis, M. Vaslamatzis, A. Polyzos, Ch. Emmanouilides, P. Katsaounis, F. Koinis, S. Xynogalos, A. Christopoulou, N. Ziras, Th. Tegos, E. Prinarakis, D. Hatzidaki, V. Georgoulias & A. Kotsakis

Authors
  1. A. Matikas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ν. Kentepozidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Ardavanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Vaslamatzis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Polyzos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ch. Emmanouilides
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Katsaounis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Koinis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Xynogalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Christopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. N. Ziras
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Th. Tegos
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E. Prinarakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. D. Hatzidaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. V. Georgoulias
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A. Kotsakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the HORG’s Lung Cancer Working Group

Corresponding author

Correspondence to A. Kotsakis.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matikas, A., Kentepozidis, Ν., Ardavanis, A. et al. Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG). Cancer Chemother Pharmacol 78, 369–376 (2016). https://doi.org/10.1007/s00280-016-3094-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-016-3094-7

Keywords

Search

Navigation